New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Advitech Announces a Definitive Distribution Agreement Of Dermylex(TM) for France and Belgium

QUEBEC — June 27, 2007 — Advitech Inc. (“Advitech” or the “Corporation”) (TSX Venture Exchange: AVI) announced today the conclusion of a Definitive Agreement (the “Agreement”) for the distribution of DermylexTM in France and Belgium with Iprad Santé S.A., a pharmaceutical corporation specialized in the development and commercialization of dermatological and gynecological products.

As per the Agreement, it is expected that the distribution of Dermylex™, in these two countries, will begin in the third quarter of 2007. Dermylex™ will be available in a network of more than 22,000 drugstores across France and Belgium. A promotional launch activity was held in Paris, France at the 2nd International Congress on Psoriasis, from June 22nd to June 24th 2007. During this congress, Dr Patrice Poubelle MD, D.Sc presented DermylexTM in one of the congress’s workshop.

“This agreement, as stated in a previous press release on April 5, 2007, is important for Advitech on two fronts: it sets up the first commercial partnership with a pharmaceutical company whose focus is dermatology and, secondly, validates Dermylex™ technological platform and clinical program following a thorough due diligence by Iprad” commented Mr. Renaud Beauchesne, president and chief executive officer of Advitech. “With this agreement for the French and Belgian markets, added to last week’s partnership announcement with Thorne Research and Diversified Natural Product for the U.S. market, Advitech is now active in two of the most important markets for dermatological products. Our sales will benefit, in the near future, from these important partnerships” added Renaud Beauchesne.

Mr. Pierre-Marie Defrance, president and chairman of Iprad Group, added: “There is a new interest from psoriasis patients for products like DermylexTM and, after analysis by our experts of the scientific and technical documentation available on DermylexTM, we are confident to effectively position Dermylex™ in the French and Belgian dermatologic markets". Iprad Santé employs 105 medical visitors and 32 commercial representatives.

About Iprad Santé S.A.

Iprad Group consists of two different business units: Iprad Laboratory develops pharmaceutical products and Iprad Santé commercializes pharmaceutical products and food supplements for the Iprad Group. Iprad Santé S.A. employs on the French and Belgian territories 105 medical visitors and 32 commercial representatives. Their main products target the dermatological and gynecological markets and they have generated, in 2006, sales of more than 40 million Euros. Iprad Group has experienced a strong growth over the past ten years and it intends to maintain this growth by adding up products specific to dermatology.

About Advitech Inc.
Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of immune-mediated inflammatory disorders, such as psoriasis and inflammatory bowel disease.

About Dermylex™
Dermylex™ developed by Advitech, is an oral natural health product relieving mild-to-moderate psoriasis symptoms. Two clinical trials, one of them multi-center, double-blind and placebo-controlled, for 112 days and on 84 patients, clinically proved the efficacy and safety of Dermylex™ for mild-to-moderate psoriasis. Dermylex™ is currently available in Canada.


This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.